An observational study in Bowel Disease, Crohn Disease and Celiac Disease, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Intestinal Diseases with a site in France — 6 open to participants now, 8 under way, 3 of them phase 3. Intestinal Diseases · France.
Among the 22 studies in Intestinal Diseases with a site in France, this one is one of 2 that started in 2023, is one of 2 observational ones, and was the 18th registered.
260 studies on the registry are indexed under Intestinal Diseases; 53 are open to participants now.
Browse Intestinal Diseases studies →6 of the 22 studies in Intestinal Diseases with a site in France are open now. Recruiting first, the newest first:
Zealand Pharma · Sites in France, United States, Austria and 11 more countries
Ages 18–90
Pfizer · Sites in France, United States, Argentina and 17 more countries
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18–65
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Turning Point Therapeutics, Inc. · Sites in France, United States, Australia and 16 more countries
Ages 12+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 38 Intestinal Diseases studies recruiting now, 17 (45%) set no upper age limit and 17 (45%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 10
First in 2003; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 236 across 74 observational studies indexed under Intestinal Diseases.
Median enrollment 180 across the 20 interventional studies, 5,100 across the 2 observational. Of the 14 that completed or were terminated, 4 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 22 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 3 studies filed under Intestinal Diseases — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Intestinal Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients participating to this study will provide images and videos of capsule endoscopy to train, tune and evaluate technological bricks of artificial intelligence solutions, in order to improve diagnostic performances of the procedure, while reducing reading time by physicians.
Capsule endoscopy is a minimally-invasive diagnostic procedure based on the ingestion (or endoscopic delivery) of a miniaturized biocompatible, camera. Capsules capture tenths of thousands images of the digestive tract. Reading the captured images and reporting is long, tedious, and at risk of errors when the reader's attention is disturbed. Artificial intelligence is expected to alleviate these limitations, by both improving diagnostic performances of capsule endoscopy while reducing reading time.
Any patient in whom a capsule endoscopy examination is performed as part of routine care will be invited to participate to the study. Their de-identified images and videos will be extracted, thus allowing the creation of several databases for training, tuning and testing technological bricks of artificial intelligence. Basic clinical data will be collected (age, gender, indication for capsule endoscopy, type of device, ingestion or delivery of capsule). Images and videos will be characterized centrally and consensually by a panel of 3 expert readers, according to their level of relevance in relation to the type and indication of capsule endoscopy.
The various, developed technological bricks will aim to automatically detect and characterize anatomical landmarks and abnormal findings, and to quote the intestine cleanliness.
Assessment of diagnostic performance and reading time will be performed within a few months or up to five years, for each technological brick, individually and then combined, according to their stepwise development.
Any patient in whom a capsule endoscopy examination is performed as part of routine care
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Any patient in whom a capsule endoscopy examination is performed as part of routine care.
Exclusion Criteria:
- Opposition to the use of images and videos from daily, routine care for research purposes.
Develop an artificial intelligence solution to help with diagnosis in VCE
Sensitivity in detection of lesions of intermediate to high relevance as identified centrally and consensually by a panel of 3 expert readers (AI vs standard reading)
Time frame: Through study completion, 5 years
Evaluation of the diagnostic performance of the A.I. solution in terms of detection
Other diagnostic performance (specificity, positive and negative predictive values, accuracy) in detection of lesions of intermediate to high relevance as identified centrally and consensually by a panel of 3 expert readers (AI vs standard reading)
Time frame: Through study completion, 5 years
Evaluation of the diagnostic performance of the A.I. solution in terms of characterisation
Time needed for detection of lesions of intermediate to high relevance as identified centrally and consensually by a panel of 3 expert readers (AI vs standard reading)
Time frame: Through study completion, 5 years
Evaluation of the diagnostic performance of the A.I. solution in terms of recognition of anatomical landmarks
Diagnostic performances in positioning anatomical landmarks (1st gastric, small bowl and colonic images) as identified centrally and consensually by a panel of 3 expert readers (AI vs standard reading)
Time frame: Through study completion, 5 years
Evaluation of the diagnostic performance of the A.I. solution in terms of quality of preparation of the various segments of the digestive tract
Diagnostic performances in quoting small bowel and colonic quality of preparation, as compared toed centrally and consensually quoted by a panel of 3 expert readers
Time frame: Through study completion, 5 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Feb 2028, 60 months after the start.
Of 35 observational studies under Intestinal Diseases, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 102. This study's planned 60 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →